These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24171517)

  • 1. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
    Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
    AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When to start antiretroviral therapy in resource-limited settings.
    Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E;
    Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda.
    Ying R; Sharma M; Heffron R; Celum CL; Baeten JM; Katabira E; Bulya N; Barnabas RV
    J Int AIDS Soc; 2015; 18(4 Suppl 3):20013. PubMed ID: 26198348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.
    Hallett TB; Baeten JM; Heffron R; Barnabas R; de Bruyn G; Cremin Í; Delany S; Garnett GP; Gray G; Johnson L; McIntyre J; Rees H; Celum C
    PLoS Med; 2011 Nov; 8(11):e1001123. PubMed ID: 22110407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.
    Mitchell KM; Lépine A; Terris-Prestholt F; Torpey K; Khamofu H; Folayan MO; Musa J; Anenih J; Sagay AS; Alhassan E; Idoko J; Vickerman P
    AIDS; 2015 Sep; 29(15):2035-44. PubMed ID: 26355574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness.
    Bassett IV; Govindasamy D; Erlwanger AS; Hyle EP; Kranzer K; van Schaik N; Noubary F; Paltiel AD; Wood R; Walensky RP; Losina E; Bekker LG; Freedberg KA
    PLoS One; 2014; 9(1):e85197. PubMed ID: 24465503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
    Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
    Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa.
    Oldenburg CE; Bärnighausen T; Tanser F; Iwuji CC; De Gruttola V; Seage GR; Mimiaga MJ; Mayer KH; Pillay D; Harling G
    Clin Infect Dis; 2016 Aug; 63(4):548-54. PubMed ID: 27208044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of antiretroviral therapy based on the 2015 WHO guidelines.
    Kuznik A; Iliyasu G; Habib AG; Musa BM; Kambugu A; Lamorde M
    AIDS; 2016 Nov; 30(18):2865-2873. PubMed ID: 27662547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.
    Freedberg KA; Kumarasamy N; Borre ED; Ross EL; Mayer KH; Losina E; Swaminathan S; Flanigan TP; Walensky RP
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):486-497. PubMed ID: 29620932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti.
    Koenig SP; Bang H; Severe P; Jean Juste MA; Ambroise A; Edwards A; Hippolyte J; Fitzgerald DW; McGreevy J; Riviere C; Marcelin S; Secours R; Johnson WD; Pape JW; Schackman BR
    PLoS Med; 2011 Sep; 8(9):e1001095. PubMed ID: 21949643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
    Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
    Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
    Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost and cost-effectiveness of transitioning to universal initiation of lifelong antiretroviral therapy for all HIV-positive pregnant and breastfeeding women in Swaziland.
    Cunnama L; Abrams EJ; Myer L; Gachuhi A; Dlamini N; Hlophe T; Kikuvi J; Langwenya N; Mthethwa S; Mudonhi D; Nhlabatsi B; Nuwagaba-Biribonwoha H; Okello V; Sahabo R; Zerbe A; Sinanovic E
    Trop Med Int Health; 2018 Sep; 23(9):950-959. PubMed ID: 29956426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health economics modeling of antiretroviral interventions amongst HIV serodiscordant couples.
    Wu H; Yu Q; Ma L; Zhang L; Chen Y; Guo P; Xu P
    Sci Rep; 2021 Jul; 11(1):13967. PubMed ID: 34234232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral Therapy for the Prevention of HIV-1 Transmission.
    Cohen MS; Chen YQ; McCauley M; Gamble T; Hosseinipour MC; Kumarasamy N; Hakim JG; Kumwenda J; Grinsztejn B; Pilotto JH; Godbole SV; Chariyalertsak S; Santos BR; Mayer KH; Hoffman IF; Eshleman SH; Piwowar-Manning E; Cottle L; Zhang XC; Makhema J; Mills LA; Panchia R; Faesen S; Eron J; Gallant J; Havlir D; Swindells S; Elharrar V; Burns D; Taha TE; Nielsen-Saines K; Celentano DD; Essex M; Hudelson SE; Redd AD; Fleming TR;
    N Engl J Med; 2016 Sep; 375(9):830-9. PubMed ID: 27424812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV prevention for high-risk groups at scale: an economic evaluation of the Avahan programme in south India.
    Vassall A; Pickles M; Chandrashekar S; Boily MC; Shetty G; Guinness L; Lowndes CM; Bradley J; Moses S; Alary M; ; Vickerman P
    Lancet Glob Health; 2014 Sep; 2(9):e531-e540. PubMed ID: 25304420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
    Gopalappa C; Stover J; Shaffer N; Mahy M
    AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.